We shape science into meaningful solutions that help people live longer, better lives.
Why it matters
When we offer new sustainable solutions to address unmet patient needs, we help improve health outcomes for more people and communities globally.
Our priorities
Innovating to improve patient lives
By generating clinical evidence, investing in R&D, pursuing partnerships and leveraging artificial intelligence, we strive to meet evolving patient needs with new health care solutions.
Ensuring quality, health and safety
Our highest priority is to ensure our products are safe and reliable. Quality is embedded across all our development processes.
Advancing health access and equity
We leverage health economics, clinical outcomes and real-world data to grow the reach of our products and help lessen inequities in health care.
2023 highlights
37M+
patients served
$1.4B
annual R&D spend1
63
active clinical trials
Zero
findings resulting in action following more than 415 external audit days
1 Represents GAAP R&D expense per Annual Report on Form 10-K.
Stories of impact
INNOVATION
Proven safety, efficacy and efficiency profile of the FARAPULSETM PFA System helps minimize risks of thermal ablation procedures
The FDA-approved FARAPULSE Pulsed Field Ablation (PFA) System brings a unique new alternative to standard-of-care thermal ablation treatment. Clinical data and real-world usage demonstrate the system is as effective in treating atrial fibrillation as thermal options and results in fewer unwanted side effects. With the FARAPULSE PFA System, patients experience statistically shorter ablation times and physicians have a quick learning curve.
On-demand digital platforms empower and support health care providers
In 2023, over 59,000 health care professionals in more than 145 countries accessed our EDUCARE platform. This on-demand platform and our ExpertLink remote connectivity solutions offer learning tools and videos, remote preceptorships, proctorships, case support and equipment assistance so providers can stay connected to our clinical and technical experts as they deliver care to patients.
INNOVATION
New stroke reduction technology advances procedural performance and safety
The WATCHMAN Left Atrial Appendage Closure Device is now the most implanted FDA-approved implant, proven to reduce stroke risk in people with atrial fibrillation not caused by a heart valve problem. To date, more than 400,000 WATCHMAN procedures have been successfully completed around the world.
MedStar Harbor Hospital creates action plan with Close the Gap, improving to #2 for statewide disparity gap measure
Close the Gap (CTG), a Boston Scientific initiative, collaborates with providers and administrators who want to make an impact around health equity. Through the Heart and Vascular Health Equity Level-up Program, CTG uncovers care disparities and helps build action plans that increase access to needed specialty care and interventions.